Ranbaxy ramps up in biosimilars, but must compete in India first
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories plans to pursue biosimilars "vigorously". Its CEO and managing director, Arun Sawhney, said recently in New York that the company expects to launch at least three biosimilar drugs in India by 2015, including an anticancer next year. Reportedly, the anticancer product could potentially rake in annual sales 'in the hundreds of millions of dollars'.